Renoprotective therapy: How good can it get?  by Hebert, Lee A.
Kidney International, Vol. 57 (2000), pp. 343–344
EDITORIAL
Renoprotective therapy: How good can it get?
A well-done randomized clinical trial is the gift that genotype is a strong risk factor for progression of renal
keeps on giving. The Ramipril Efficacy in Nephropathy disease. Vleming reports that in 20 of 22 studies involving
(REIN) study is no exception. In the latest gift of new 3153 renal disease patients, the DD genotype was associ-
knowledge from the REIN study, Perna and colleagues ated with a 1.2 to 6.4 relative risk of progression of
have re-examined the study outcomes in light of new renal disease compared to the II or the combined II,
data: the angiotensin-converting enzyme (ACE) geno- ID genotypes [2]. This study by Perna and colleagues
type of the study patients [1]. involved a relatively small number of patients (N 5 212).
This gift is particularly welcome because it is an exam- Thus, key finding #1 is vulnerable to a type II statistical
ple of an investigation that tested for an interaction be- error (failure to find a difference because of small sample
tween the patients’ genotype [ACE gene insertion (I)/ size).
deletion (D) polymorphism] and a clinical intervention With regard to key finding #2, William of Occam and
(therapy with ramipril versus placebo) on a disease out- I have no problem (well, at least not a big problem).
come (progression of renal disease). Most genetic studies Indeed, Bill and I would expect ACE inhibitor therapy
simply examine the association between genotype and to be particularly effective under conditions of high ex-
disease. Such studies may be confounded if there is a pression of ACE (the DD polymorphism). It is the sim-
strong interaction between genotype and clinical factors plest explanation. However, we were surprised that ACE
such as therapy. This analysis by Perna and colleagues inhibitor therapy had zero effect on renal disease pro-
shows how important it can be to search for the influence gression in the II and ID genotypes. Perhaps that too
of genotype and clinical interactions on disease outcome. could be the type 2 error “bug.” In any event, that bug
Their key findings are: will likely be squashed in the next few years as the several
large-scale clinical trials on the therapy of renal disease
1. The I/D genotype of the REIN patients did not sig- progression are completed.
nificantly influence progression of renal disease In the meanwhile, Bill and I suggest that these findings
(GFR decline rate or the incidence of end-stage renal by Perna and colleagues should not influence patient
disease). management. This work is surely trailblazing and provoc-
2. Ramipril protected against progression of renal dis- ative, however, it is not a definitive analysis of the influ-
ease, but only in those with the DD genotype. ence of ACE inhibitor therapy on progression of renal
disease. Specifically:
Although the key findings are clear, they appear to 1. The achieved blood pressures in the REIN study
contradict each other. If possessing the DD genotype were relatively high. The MDRD study showed that
(high expression of angiotensin II) is not harmful to the achieving a systolic blood pressure in the 120s mm Hg
function of diseased kidneys (key finding #1), why should slows progression of renal disease better than a systolic
thwarting the effect of the DD genotype (ACE inhibitor blood pressure in the 130s mm Hg [3]. In the REIN
therapy) be beneficial to the function of diseased kidneys study, the mean achieved systolic blood pressure was
(key finding #2)? Some might argue that the DD geno- about 144 mm Hg. The REIN study renal outcomes
type may promote progression of renal disease by mecha- might have been different if lower blood pressure levels
nisms that do not involve angiotensin II but are blocked had been achieved.
by ACE inhibitors. However, William of Occam’s razor 2. The REIN study used moderate-dose ACE inhibitor
would make mincemeat of that hypothesis because it is therapy. If higher dose ACE inhibitor therapy had been
not the simplest explanation of the data, and it requires used, progression of renal disease might have been differ-
postulating mechanisms that are not known to exist. ent among the I/D cohorts from that reported.
Contrary to the key finding #1, Vleming’s very recent 3. Angiotensin II’s effects are but one mechanism of
extensive review provides strong evidence that the DD progression of renal disease. Perhaps this is the most
important point. Almost certainly optimum renoprotec-
tive therapy requires multiple interventions. Also, theKey words: genotype, end-stage renal disease, ramipril, progressive
renal disease. way in which these interventions interact may critically
determine efficacy of renal protection. Thus, there is still 2000 by the International Society of Nephrology
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much to be learned about the optimum use of ACE and segmental glomerulosclerosis (FSG) is over-repre-
sented in populations that exhibit insulin resistance suchinhibitors in renal protection.
In light of the above, what can be recommended as as the obese and African Americans [8]. When these
patients develop renal disease, exercise, weight reduc-prudent and practical therapy for the mitigation of renal
disease progression? For this discussion, I have excused tion, and diet low in refined sugars can be recommended
to lower C-peptide levels. If that fails, metformin orBill. My colleagues and I at The Ohio State University
Nephrology Division can handle this better without him troglitazone, therapies that lower insulin levels but do
not promote hypoglycemia, might be appropriate.(he is too picky). We use the following approach in all
patients vulnerable to renal disease progression. The Is this as good as renoprotective therapy gets? Of
course, we don’t know. That would require a prospectiverationale of our approach is a plausible, but long story.
The short version is as follows: trial in which patients with renal disease are randomized
to usual care or to an intensive multiple-risk factor inter-1. Control blood pressure. The goal is a sitting systolic
vention (did somebody say MR FIT?). I even have ablood pressure in the 120s mm Hg or lower, if tolerated
name for such a study: The MR KIDNEY study. For[3]. Home blood pressure is preferred [4]. The blood
just a few million dollars a year, the NIH could obtainpressure goal is particularly important in proteinuric Af-
naming rights to the study. It is just a suggestion.rican Americans [5].
2. ACE inhibitor or angiotensin receptor blocker
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